Robert Gian Carlo Rando

6355785, Mar 12, 2002

Oct 28, 1999

09/429130

Robert F. Rando - The Woodlands TX
Susan Fennewald - The Woodlands TX
Joseph G. Zendegui - The Woodlands TX
Joshua O. Ojwang - Spring TX
Michael E. Hogan - The Woodlands TX
Yves Pommier - Bethesda MD
Abhijit Mazumder - Bethesda MD

Aronex Pharmaceuticals, Inc. - The Woodlands TX

C07H 2100

536 231, 536 245, 536 253, 514 44, 435 6

A method and compositions for treating viral infection (IV) vitro and in vivo using a guanosine-rich oligonucleotide. The oligonucleotides have sufficient guanosine to form a guanosine tetrad. Also provided are oligonucleotides of at least two runs of at least two guanosines. Also provided are guanosine-rich oligonucleotides and methods for treating viral infections in humans, and a method for designing guanosine-rich oligonucleotides having anti-viral activity and integrase inhibition activity.

6583149, Jun 24, 2003

Sep 22, 2000

09/667326

Francis J. Giles - Houston TX
Jean Bédard - Rosemere, CA
Robert F. Rando - Annandale NJ

BioChem Pharma Inc.

A01N 4354

514274, 514262, 514269

Compounds of formula I: wherein Y, X, R1 and Ra are defined herein are in methods for treating or preventing a viral infections selected from herpes simplex virus, varicella zoster virus, respiratory syncytial virus and cytomegalovirus infections.

6964968, Nov 15, 2005

Mar 31, 2003

10/401727

Francis J. Giles - Houston TX, US
Jean Bédard - Quebec, CA
Robert F. Rando - Annandale NJ, US

Shire Biochem, Inc. - Ville Saint-Laurent

A01N043/54
A01N043/90
A61K031/505
A61K031/52

514274, 5142581, 514262, 514269, 514463, 514464

Viral infections selected from the group consisting of herpes simplex virus, varicella zoster virus, respiratory syncytial virus and cytomegalovirus can be treated by administering to the host a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof; wherein Y, Ra, and R1 are as defined herein. The compounds and salts can also be used to inhibit viral replication of these viruses in cells.

7074769, Jul 11, 2006

Jan 2, 2001

09/753169

Cy A. Stein - New City NY, US
Paul Cossum - The Woodlands TX, US
Robert Rando - Annandale NJ, US
Joshua Ojwang - Edmond OK, US

The Trustees of Columbia University in the City of New York - New York NY
Aronex Pharmaceuticals, Inc. - Lexington MA

A01N 43/04
A61K 31/70
C07H 21/00
C07H 21/04

514 44, 536 243, 536 2431, 536 2433, 536 245

This invention provides an antisense oligonucleotide or analog thereof comprising 10 or more contiguous bases or base analogs from the sequence of bases of sequence A, B, C, D, E, F, G, H, I, J, K, L, or M of FIG. This invention also provides the above-described antisense oligonucleotides, wherein the nucleotide sequence comprises nucleotide sequence A, A′, B, C, C′, D, E, E, E′, F, G, G′, H, H′, I, I′, J, K, K′, L, L′, M, or M′ of FIGS. A and B. This invention also provides the above-described antisense oligonucleotides, wherein the oligonucleotide is encapsulated in a liposome or nanoparticle. This invention also provides the above-described antisense oligonucleotides, wherein the phosphate backbone comprises phosphorothioate bonds. In addition, this invention provides a method of treating cancer, comprising introducing into a tumor cell an effective amount of the the above-described antisense oligonucleotide, thereby reducing the levels of bcl-xL protein produced and treating cancer. This invention also provides the above-described methods, wherein the introducing comprises using porphyrin or lipofectin as a delivery agent.

56503164, Jul 22, 1997

Jun 6, 1994

8/254114

Bharat B. Aggarwal - Houston TX
Robert F. Rando - The Woodlands TX
Michael E. Hogan - The Woodlands TX

Research Development Foundation - Carson City NV

C12N 510
C07H 2104
C12Q 168
G01N 33574

435375

The present invention provides novel methods of treating anti-neoplastic and non-neoplastic cell proliferative diseases. The present methods involve administration of triplex forming oligonucleotides to humans to inhibit the biological activity of tumor necrosis factor. Also provided are methods of treating neuro-oncologic states and renal cancer.

55676049, Oct 22, 1996

Oct 28, 1993

8/145704

Robert F. Rando - The Woodlands TX
Susan Fennewald - The Woodlands TX
Joseph G. Zendegui - The Woodlands TX
Joshua O. Ojwang - Spring TX

Aronex Pharmaceuticals, Inc. - The Woodlands TX

C12N 706

435238

A method and compositions for treating viral infection in vitro and in vivo using a guanosine-rich oligonucleotides. The oligonucleotides are composed of at least about 50% guanosine nucleotides. Also provided are guanosine-rich oligonucleotides and methods for treating viral infections in humans, and a method for designing guanosine-rich oligonucleotides having anti-viral activity.

61843695, Feb 6, 2001

Oct 23, 1995

8/535168

Robert F. Rando - The Woodlands TX
Susan Fennewald - The Woodlands TX
Joseph G. Zendegui - The Woodlands TX
Michael E. Hogan - The Woodlands TX

Aronex Pharmaceuticals, Inc. - The Woodlands TX

C07H 2100
C07H 2102
C07H 2104

536 231

The oligonucleotides have sufficient guanosine to form a guanosine tetrad and can be composed of at least about 40% guanosine nucleotides, the nucleotide sequence containing at least two runs of at least two guanosines. Some of the new oligonucleotides also contain phosphorothioate backbones and 3' end modifications. Representative guanosine-rich oligonucleotides of the present invention demonstrate anti-viral activity in tissue culture against HSV-2, HIV-1, HCMV and FMLV, and show specific inhibition of bacterial RNA polymerase enzymes T7 and T3, the FMLV and HIV-1 reverse transcriptase enzyme and eukaryotic RNA polymerase.

54460450, Aug 29, 1995

Dec 20, 1993

8/170559

Ganapathi R. Revankar - The Woodlands TX
Arthur F. Lewis - The Woodlands TX
Birendra K. Bhattacharya - The Woodlands TX
Rodrigo V. Devivar - Spring TX
Robert F. Rando - The Woodlands TX
Susan M. Fennewald - The Woodlands TX

A61K 31505

514258

A series of guanine analogs having the basic structures of ##STR1## and physiological salts thereof. Also disclosed are a variety of the use of the compounds as a composition with a physiological carrier or in combination therapy with acyclovir, HBG and ganciclovir in the treatment of viral disease.